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ABSTRACT
Objectives: To investigate the association between
antidepressant therapy and the later onset of mania/
bipolar disorder.
Design: Retrospective cohort study using an
anonymised electronic health record case register.
Setting: South London and Maudsley National Health
Service (NHS) Trust (SLaM), a large provider of
inpatient and community mental healthcare in the UK.
Participants: 21 012 adults presenting to SLaM
between 1 April 2006 and 31 March 2013 with
unipolar depression.
Exposure: Prior antidepressant therapy recorded in
electronic health records.
Main outcome measure: Time to subsequent
diagnosis of mania or bipolar disorder from date of
diagnosis of unipolar depression, censored at 31
March 2014.
Methods: Multivariable Cox regression analysis with
age and gender as covariates.
Results: The overall incidence rate of mania/bipolar
disorder was 10.9 per 1000 person-years. The peak
incidence of mania/bipolar disorder incidence was seen
in patients aged between 26 and 35 years (12.3 per
1000 person-years). Prior antidepressant treatment
was associated with an increased incidence of mania/
bipolar disorder ranging from 13.1 to 19.1 per 1000
person-years. Multivariable analysis indicated a
significant association with selective serotonin reuptake
inhibitors (HR 1.34, 95% CI 1.18 to 1.52) and
venlafaxine (1.35, 1.07 to 1.70).
Conclusions: In people with unipolar depression,
antidepressant treatment is associated with an
increased risk of subsequent mania/bipolar disorder.
These findings highlight the importance of considering
risk factors for mania when treating people with
depression.
INTRODUCTION
The occurrence of mania and hypomania
in people receiving antidepressant therapy
is an adverse effect of treatment with
antidepressant medication.1 However, it is
unclear whether antidepressants cause acute
mania or hypomania in patients with uni-
polar depression or trigger the expression of
an underlying bipolar disorder.2 Acute
mania has been particularly associated with
TCAs and dual-action antidepressants such as
venlafaxine.1 3
As patients with bipolar disorder typically
present during a depressive or mixed affect-
ive episode rather than during a hypomanic
or manic episode,4 and depressive symptoms
tend to dominate the course of the illness,5 6
a proportion of patients treated for unipolar
depression may have an underlying bipolar
disorder.7 8
Previous ﬁndings exploring this area have
been derived from data compiled from a
number of studies that differ in type, size
and design, and often without the explicit
goal of identifying the rate of mania or hypo-
mania in patients with unipolar depression.1
Strengths and limitations of this study
▪ The findings were drawn from a large population
(over 21 000 adults) using data from electronic
health records which are representative of every-
day clinical practice. The results are therefore
generally applicable.
▪ Because it was an observational study, it is not
possible to infer a causal link between anti-
depressant treatment and an increased incidence
of mania or bipolar disorder.
▪ Although the findings are based on data
recorded when patients were receiving secondary
mental healthcare, most will have originally been
diagnosed with depression and initially treated in
primary care. Some of these patients may have
developed mania prior to contact with secondary
mental healthcare services, resulting in an under-
estimate of the incidence of mania/bipolar
disorder.
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An investigation focusing on incidence in a ‘real-world’
sample receiving routine care may give a more meaning-
ful estimation of the association of antidepressants with
mania or hypomania. In the present study, we examined
the electronic health records of a large sample of
patients receiving secondary mental healthcare for uni-
polar depression. We extracted data on prior antidepres-
sant use and subsequent diagnosis of mania or bipolar
disorder, then tested the hypothesis that antidepressant
exposure was associated with an increase in incidence of
subsequent mania or bipolar disorder.
METHODS
Participants
We included all individuals aged between 16 and 65
receiving mental healthcare from the South London
and Maudsley National Health Service (NHS)
Foundation Trust (SLaM) between 1 April 2006 and 31
March 2013 with a diagnosis of depression
(International Classiﬁcation of Diseases (ICD)-10 F32/
F33), and no prior diagnosis of mania or bipolar dis-
order (F30/F31). Applying these inclusion criteria
yielded a sample of 21 012 patients. The follow-up
period was from the date that depression was ﬁrst diag-
nosed to 31 March 2014 and comprised 91 110 person-
years with a mean follow-up duration of 4.3 years.
Source of clinical data
Data were obtained for this study from the SLaM
Biomedical Research Centre (BRC) Case Register.9
SLaM is a large provider of mental healthcare covering a
catchment area of around 1.2 million residents in South
London. Clinical records in SLaM have been documen-
ted in a single electronic health record system (the elec-
tronic Patient Journey System—ePJS) since April 2006.
Anonymised clinical data from ePJS including structured
ﬁelds (for demographic, diagnostic and medication
data) and pseudonymised unstructured free-text ﬁelds
from case notes and correspondence have been
extracted into the SLaM BRC Case Register.10 Clinical
information is documented by healthcare professionals
during the course of providing mental healthcare to
patients and includes history, mental state examination,
diagnostic formulation and management plans. The
healthcare professionals who document clinical data
include psychiatrists, psychologists, nursing staff, care
coordinators and allied healthcare professionals.
Diagnostic information is generally recorded by a psych-
iatrist and is based on clinical interview. Data for this
study were obtained from these sources of clinical data
in the SLaM BRC Case Register using the Clinical
Record Interactive Search tool (CRIS). CRIS is a
bespoke database search and assembly tool which has
supported a range of studies using this data set.11–16
CRIS obtains data from the SLaM BRC Case Register
from structured electronic health record ﬁelds and also
using natural language processing (NLP) from
unstructured free-text documentation. In order to maxi-
mise ascertainment of diagnosis and prior antidepres-
sant treatment in this study, data on these variables were
obtained from both structured ﬁelds and unstructured
free-text clinical entries (using NLP).17
Ascertainment of prior antidepressant therapy
Prior antidepressant therapy was deﬁned as documenta-
tion of antidepressant treatment prior to the date of
diagnosis of depression. This deﬁnition was chosen on
the basis of a previous study which indicated that in the
SLaM BRC Case Register, the documentation of treat-
ment for a mental health disorder generally occurs prior
to the documentation of a formal diagnosis.18 For the
purposes of this study, antidepressants were deﬁned as
any licensed antidepressant medication listed in section
4.3 of the British National Formulary (BNF)19 in the fol-
lowing groups: Monoamine-oxidase inhibitors; mirtaza-
pine; selective serotonin reuptake inhibitors (SSRI);
TCAs; trazodone; venlafaxine; duloxetine; other antide-
pressants (agomelatine and reboxetine). These groups
were chosen based on the UK National Institute for
Health and Care Excellence (NICE) guideline (CG90)
for treatment and management of depression in
adults.20 Each of these groups was analysed as a binary
variable deﬁned as treatment with any drug within each
group.
Clinical outcome measures and covariates
The primary outcome measure was a diagnosis of mania
or bipolar disorder (F30/F31) during the follow-up
period. Age and gender recorded closest to the date of
diagnosis of depression were included as covariates.
Statistical analysis
The data were analysed using Stata (V.12.0).21
Descriptive statistics for all variables were obtained as fre-
quencies and percentages. The association of prior anti-
depressant therapy and subsequent diagnosis of mania/
bipolar disorder was investigated using survival analysis
and multivariable Cox regression. For these analyses, the
outcome variable of time to diagnosis of mania/bipolar
disorder was deﬁned as the number of years from the
date of diagnosis of depression to the date of diagnosis
of mania/bipolar disorder, censored at 31 March 2014.
Incidence rates of mania/bipolar disorder were esti-
mated for the overall population in the study and for
subgroups deﬁned by prior antidepressant treatment,
age and gender. Unadjusted and adjusted HRs were esti-
mated using univariate and multivariable Cox regres-
sion. The multivariable model included age, gender and
prior antidepressant treatment (in the groups deﬁned
previously) in order to adjust for prior treatment with
more than one antidepressant. Reference groups for age
and gender in the Cox regression analysis were deﬁned
as those with the greatest prevalence for each variable.
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RESULTS
Incidence rate of mania/bipolar disorder
Of the 21 012 patients included in the study, 994 were
diagnosed with mania or bipolar disorder during the
follow-up period. The overall incidence rate of mania/
bipolar disorder was 10.9 per 1000 person-years.
Sample characteristics and association of antidepressant
therapy with subsequent mania/bipolar disorder
Table 1 summarises the breakdown of demographic
factors and prior antidepressant treatment within the
sample and their association with subsequent mania or
bipolar disorder. The majority of the sample were
female and aged between 26 and 35 years, and these
groups were associated with the peak incidence of
mania/bipolar disorder. The most frequently prescribed
antidepressants were SSRIs (35.5%), mirtazapine
(9.4%), venlafaxine (5.6%) and TCAs (4.7%). All anti-
depressants were associated with an increased incidence
of mania/bipolar disorder (unadjusted HR>1.0 for all
antidepressants) with incidence rates ranging from 13.1
(TCAs) to 19.1 (trazodone) per 1000 person-years.
Multivariable Cox regression analysis (adjusted for age,
gender and previous antidepressant treatment) indi-
cated a statistically signiﬁcant association of prior treat-
ment with SSRIs (HR 1.34, 95% CI 1.18 to 1.52) and
venlafaxine (1.35, 1.07 to 1.70).
DISCUSSION
Our ﬁndings demonstrate a signiﬁcant association
between antidepressant therapy in patients with unipolar
depression and an increased incidence of mania. This
association remained signiﬁcant after adjusting for age
and gender.
The overall incidence of mania, independent of treat-
ment, was 10.9 per 1000 person-years. A study by
Benvenuti et al22 found an incidence rate of mania of
3.0% in patients with unipolar depression treated with
SSRIs, and 0.9% in those patients treated with interper-
sonal psychotherapy over a 9-month follow-up period
and a study in children and young adults by Martin
et al23 found a rate of 5.4% over a median follow-up of
41 weeks. A recent meta-analysis estimated even greater
rates of mania of 12.5% for those treated with antide-
pressants.1 These estimates from previous studies are
greater than the rate found in the present study. In
another retrospective study, patients with unipolar
depression showed a prevalence of mania of 13.1% over
a 6-year follow-up period, whereby the group which
developed mania also had a higher frequency of family
history of bipolar disorder than those who did not
develop mania.24 In the present study, the HR of
mania/bipolar disorder associated with antidepressant
therapy ranged between 1.11 and 1.47. This compares
with antidepressant-associated mania HRs of between
2.1 and 3.9 by Martin et al.23 Another study in which
patients with underlying bipolar disorder were treated
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with antidepressant monotherapy without a mood stabili-
ser, the HR was found to be 2.83 vs 0.79 in patients
treated with a concurrent mood stabiliser.25 Venlafaxine
and SSRIs were consistently associated with mania/
bipolar disorder in our study. These ﬁndings are in
keeping with previously established associations of mania
with venlafaxine,1 26–29 as well as SSRIs.1 30–32 It is pos-
sible that the incidence rate of mania and HR associated
with antidepressant therapy in our study was lower than
previous studies because the sample was drawn from
patients presenting to secondary mental healthcare ser-
vices. Patients presenting to mental healthcare services
with unipolar depression may have already received anti-
depressant therapy from primary care services.
Furthermore, patients may have developed symptoms of
mania prior while being treated with antidepressants in
primary care and would have presented to secondary
care services already with an established diagnosis of
bipolar disorder.
Antidepressant-induced mania has been reported
more commonly in people with an established diagnosis
of bipolar disorder than in people with unipolar depres-
sion.30 It is generally recommended that patients who
have been previously diagnosed with depressive disor-
ders while experiencing manic or hypomanic episodes
on antidepressant therapy should be evaluated for
bipolar disorder. The different therapeutic approach to
unipolar depression versus bipolar disorder has initiated
discussion on misdiagnosis in cases of patients with uni-
polar depression who subsequently experience episodes
of hypomania or mania. Approximately half of initial
episodes of bipolar disorder present initially with depres-
sion,4 and depressive symptoms tend to dominate the
course of the illness.5 6 In cases in which a diagnosis of
bipolar disorder had been previously established, epi-
sodes of mania have been particularly associated with
TCAs and venlafaxine.3 However, it is possible that the
association of hypomania or mania with antidepressant
therapy in people with a diagnosis of unipolar depres-
sion reﬂects an underlying bipolar depression rather
than an adverse effect of antidepressants. There is
ongoing debate regarding the nosological distinction
between unipolar and bipolar depression7 8 and the
extent to which these two disorders can be distinguished
in the absence of a prior episode of mania or
hypomania.8
However, regardless of underlying diagnosis or aeti-
ology, the association of antidepressant therapy with
mania demonstrated in the present and previous studies
highlights the importance of considering whether an
individual who presents with depression could be at risk
of future episodes of mania.33 34 Apart from antidepres-
sant therapy, other risk factors for mania or hypomania
in people receiving treatment for depression include a
family history of bipolar disorder, a depressive episode
with psychotic symptoms, young age at onset of depres-
sion and antidepressant resistance.35 Although we were
unable to obtain data on family history of bipolar
disorder, the presence of psychotic symptoms or anti-
depressant resistance in our study, we did ﬁnd a greater
incidence of mania/bipolar disorder in patients aged
between 26 and 35 years, in keeping with previous ﬁnd-
ings.23 Future research should not only focus on which
classes of antidepressants are most associated with
mania, but also on other associated factors in order to
guide clinicians of the risk of mania in people with
depression prior to prescribing antidepressant therapy.
There are some limitations which should be consid-
ered when interpreting the results presented in our
study. Our ﬁndings are based on observational data, and
so it is not possible to infer an aetiological association
between antidepressant exposure and subsequent
mania/bipolar disorder. The use of routinely recorded
clinical data also meant we were unable to obtain data
on potentially important factors such as family history of
bipolar disorder, the presence of psychotic symptoms or
resistance to antidepressant therapy. Our ﬁndings were
based on data recorded from adults in secondary mental
healthcare services. It is likely that the patients included
in our study will have received a diagnosis of depression
and initial treatment in primary care. It is also possible
that patients who received treatment in secondary care
may have been discharged back to primary care where
their treatment may have been modiﬁed. Our study did
not include patients who developed an episode of mania
prior to receiving initial treatment in secondary mental
healthcare services or prior to the age of 16 years. These
patients would have been excluded from our study
thereby leading to an underestimate of mania/bipolar
disorder incidence. Further research is warranted to
investigate clinical data recorded in patients under the
age of 16 and linking data from primary care services
with data from secondary care services to establish asso-
ciation of antidepressant therapy with mania across both
clinical settings. Another limitation was the lack of avail-
able data on timing or dose of antidepressant therapy. It
is possible that any association between antidepressant
therapy and subsequent mania/bipolar disorder would
have depended on the dose and duration of treatment,
and in patients who did develop mania, how soon a par-
ticular antidepressant was given prior to the onset of
symptoms of mania. Furthermore, some patients may
have been switched between different antidepressants
(due to lack of efﬁcacy in treating depression) prior to
onset of mania. As the antidepressant exposure in our
study was determined prior to onset of mania, it is not
possible to determine which antidepressants (if any) a
patient was taking at the time of onset of mania.
We found an association of venlafaxine with subse-
quent mania/bipolar disorder. In the UK, venlafaxine is
recommended as a second-line treatment for unipolar
depression.20 It is therefore possible that this association
is confounded by resistance to antidepressant therapy.
Furthermore, the analysis of routine clinical records
raises the possibility of confounding by indication,
whereby the choice of pharmacotherapy employed by
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clinicians is inﬂuenced by their perception of likely
beneﬁcial or adverse effect. It is possible that other
factors associated with mania could have inﬂuenced the
choice of antidepressant therapy, therefore biasing our
ﬁndings with respect to the observed association of anti-
depressant therapy with mania/bipolar disorder. This
might explain why we did not elicit an association of
TCAs with subsequent mania in our study despite previ-
ous studies suggesting this possibility.1 Another possible
explanations for the lack of association of TCAs with
mania in our study is their use for other clinical indica-
tions such as neuropathic pain (often at lower doses
than used to treat depression) which could have
reduced their association with mania.36
In our study, we only analysed the association of anti-
depressant therapy with subsequent mania or bipolar
disorder. Treatment guidelines recommend that patients
who do not respond to antidepressant monotherapy
may beneﬁt from augmentation with an antipsychotic or
mood stabiliser.20 We were unable to reliably obtain data
on antidepressant augmentation in our study. However,
it is possible that augmentation with such agents may
have affected any observed association of antidepressant
therapy with the development of mania/bipolar dis-
order as antipsychotics and mood stabilisers have been
shown to reduce the risk of developing mania37 and
further studies are warranted to investigate the associ-
ation of antidepressant augmentation on risk of mania.
Despite these limitations, we have demonstrated an
association between antidepressant therapy and subse-
quent mania/bipolar disorder using a large data set of
clinical data that is prospectively recorded and represen-
tative of everyday clinical practice in secondary mental
healthcare. Our ﬁndings are therefore generalisable to
people receiving standard antidepressant therapy for
depression and in keeping with previous studies drawn
from observational and interventional research studies.
Although our ﬁndings do not demonstrate any causal
link between antidepressant therapy and bipolar dis-
order, the association of antidepressant therapy with
mania in people being treated for depression reinforces
the importance of considering risk factors for mania or
hypomania in people who present with an episode of
depression. Our ﬁndings also highlight an ongoing
need to develop better ways to predict future risk of
mania in people with no prior history of bipolar dis-
order who present with an episode of depression.
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